Navigation Links
Chiasma to Present at the UBS Global Life Sciences Conference
Date:9/14/2011

NEW YORK and JERUSALEM, Sept. 14, 2011 /PRNewswire/ -- Chiasma, Inc., a privately held biopharma company, announced that Fredric Price, Chiasma's Chairman & CEO, will present an overview of the Company at the UBS Global Life Sciences Conference at the Grand Hyatt, New York, New York, on Monday, September 19, 2011 at 1:30 PM.

Chiasma's investigational new drug Octreolin™ is an oral form of octreotide acetate being developed first for the oral treatment of acromegaly, a hormonal disorder that results from an excess of growth hormone.  The Company successfully completed 4 clinical studies with Octreolin in healthy volunteers, having established a pharmacokinetics profile similar to that of subcutaneously injected octreotide acetate.  In addition, Octreolin demonstrated the ability to reduce growth hormone.  No serious adverse safety events were reported in any of the studies.  A trial in patients will commence in October 2011.  Chiasma intends to file an NDA using the 505(b)(2) regulatory pathway in the US and its EMA equivalent, the Hybrid Application in Europe.

Octreolin is also being developed as a chronic treatment for patients with Portal Hypertension (PHT); a Phase 2 proof of concept trial for this new orphan indication (no drugs are approved for PHT in the US) was initiated in September 2011.  The Company has a pipeline of products that are currently in preclinical development including one in renal disease that will enter the clinic in mid-2012.

About Chiasma

Chiasma develops new drug products based on its proprietary Transient Permeability Enhancer (TPE) technology, which enables oral delivery of macromolecules (up-to 20 kDa) and poorly-absorbed small molecules into the portal system and then to the systemic circulation.  The TPE technology not only enables their being converted from injectable to oral, but importantly can result in the development of new indications.

Chiasma is a Delaware corporation with a 100% owned Israeli subsidiary.  It is backed by MPM Capital, ARCH Venture Partners, F-2 Ventures and 7 Med Health Ventures.

Additional information can be found at:  www.ChiasmaPharma.com.

Forward-Looking Statements

This press release contains forward-looking statements about the business, goals and prospects of Chiasma, Inc., including, without limitation, statements about the development of drugs in the TPE system.  These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements.  Chiasma is under no obligation, and expressly disclaims any obligation, to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Chiasma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Chiasmas Octreolin™ (Oral Octreotide) Shown to Inhibit Growth Hormone in Healthy Subjects
2. Chiasma Grants Option to License Transient Permeability Enhancer (TPE) Technology for Small Molecule Products
3. Savient Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
4. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
5. Heska to Present at LD MICRO Invitational on September 22, 2011
6. Isis Pharmaceuticals to Present at the UBS Global Life Sciences Conference
7. BioMarin to Present at the UBS Global Life Sciences Conference
8. Henry Schein to Present at the CL King 9th Annual Best Ideas Conference 2011
9. PDL BioPharma to Present at Upcoming Investor Conferences
10. Pacira Pharmaceuticals, Inc. to Present at UBS Global Life Sciences Conference
11. Positive Results From Avanafil Phase 3 Study in Diabetics Presented at the 47th EASD Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... According to a new market report ... U.S. Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 ... was valued at US$ 5.89 Bn in 2014 and is ... to 2023 to reach US$ 7.99 Bn in 2023. ... needle free drug delivery devices and the market is estimated ...
(Date:5/26/2016)... A key trend that will ... of new treatments. Cardax, a development stage life sciences ... therapy is expected to fulfil large unmet medical needs ... studies to develop new treatments for osteoarthritis. One such ... in osteoarthritis are being investigated, and early trials of ...
(Date:5/26/2016)... 2016 TARE (Transarterial Radio-embolization) ... Savings and Overall Decreased Use of Hospital ... international specialist healthcare company, has today announced the ... Meeting of ISPOR (International Society for Pharmacoeconomics and ... (HCC) using yttrium-90 glass microspheres is associated with ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... 2016 , ... OncLive® , a leading digital provider ... University of Virginia (UVA) Cancer Center to its quickly expanding Strategic ... will publicize and promote public awareness of UVA Cancer Center’s latest advances in ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... organization to provide strategic sales leadership and to further develop their rapidly expanding ... B.S. in Business Administration with a concentration in Marketing and an M.B.A. with ...
(Date:5/26/2016)... ... ... Dr. LeRoy Perry’s recently authored whitepaper, “Tech Neck and ROI (return on ... users, hundreds of millions of whom are coming into the workplace with pain in ... action of looking down at hand-held technology devices (tablets, smartphones) for extended periods of ...
(Date:5/26/2016)... ... , ... In 1980, Bill Howe opened AM/PM Sewer and Drains as a ... to grow the company was built on a simple mission of providing qualified San ... and customer service. Over 35 years later, Bill Howe remains one of the largest ...
(Date:5/26/2016)... ... May 26, 2016 , ... TopConsumerReviews.com ... Blood Pressure products . , High blood pressure affects millions of people worldwide, ... blood pressure can lead to heart disease, stroke, kidney disease, and hardening of ...
Breaking Medicine News(10 mins):